| abstract |
Provided herein are biomarker proteins whose changes in concentration or activity level are associated with clinically significant treatment of aHUS using atypical hemolytic uremic syndrome (aHUS) or complement inhibitors. Also provided are compositions and methods for examining the concentration and/or activity of one or more biomarker proteins in a biological fluid. Compositions and methods, in particular, assess the risk of developing aHUS, and/or diagnose aHUS, and/or determine whether a subject has the first acute signs of aHUS, and/or monitor the progression or remission of aHUS, and/or complement It is useful to monitor response to treatments using inhibitors or to optimize such treatments. |